Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959426 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00959426 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 71 participants.
The verdict
NCT00959426, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of PF-04620110.
Interventions
- DRUG Placebo
- DRUG PF-04620110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00959426
The ClinicalTrials.gov registry entry for NCT00959426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00959426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00959426 about?
NCT00959426 is a clinical study titled "A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers". PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of PF-04620110.
What is the current status of trial NCT00959426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2009-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00959426?
The interventions under investigation include: Placebo (DRUG), PF-04620110 (DRUG).
Who is sponsoring clinical trial NCT00959426?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.